medigraphic.com

2014, Número 5

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2014; 52 (5)


Los bloqueadores β-1 adrenérgicos reducen la respuesta a estímulos dolorosos en neuronas de amplio rango dinámico de la médula espinal en ratas

Lamothe-Molina PJ, Lamothe-Molina PA, López-Ávila A

Idioma: Español
Referencias bibliográficas: 32
Paginas: 494-501
Archivo PDF: 337.33 Kb.


RESUMEN

Introducción: la epinefrina/norepinefrina inhibe la transmisión del dolor agudo; empero, no es claro el papel de los receptores β-adrenérgicos. Por tanto, analizamos si los fármacos de estos receptores modulan la transmisión del dolor agudo mediante registro electrofisiológico unitario extracelular in vivo durante estimulación periférica dolorosa y no dolorosa en ratas.
Métodos: estudio longitudinal en el que se cotejaron siete grupos de ratas: control (n = 11): solución salina (0,9 %); EPI (n = 8): 100 mcg epinefrina; AGOβ1 (n = 8): 125 mcg dobutamina; ANTβ1 (n = 9): 100 mcg metoprolol; AGOβ2 (n = 7): 100 mcg clembuterol; ANTβ2 (n = 8): butoxamina 100 mcg; ANTβ1 + EPI (n = 10): 100 mcg metoprolol + 100 mcg epinefrina. Se hizo análisis estadístico por medio de ANOVA.
Resultados: La epinefrina redujo significativamente la tasa de disparo basal (RDB) en 34.1 % (p ‹ 0.05) y la respuesta evocada por la estimulación dolorosa en 56 % (p ‹ 0.05). No hubo cambios en la respuesta provocada por la falta de estimulación dolorosa. El ANTβ1 fue el único fármaco con acción β-adrenérgica que redujo significativamente la respuesta evocada por la estimulación dolorosa en 41 % (p ‹ 0.05).
Conclusión: por primera vez un antagonista de los receptores β1-adrenérgicos (metoprolol) prueba ser eficaz en la reducción de la respuesta a la estimulación dolorosa en las neuronas ARD.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Butler RK, Finn DP. Stress-induced analgesia. Prog Neurobiol. 2009;88(3):184-202.

  2. Akil H, Young E, Walker JM, Watson SJ. The many possible roles of opioids and related peptides in stress-induced analgesia. Ann NY Acad Sci. 1986;467:140-53.

  3. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005 Jun 23;435(7045):1108-12.

  4. Killian P, Holmes BB, Takemori AE, Portoghese PS, Fujimoto JM. Cold water swim stress- and delta-2 opioid-induced analgesia are modulated by spinal gamma-aminobutyric acidA receptors. J Pharmacol Exp Ther. 1995 Aug;274(2):730-4.

  5. Lico MC, Hoffmann A, Covian MR. Infl uence of some limbic structures upon somatic and autonomic manifestations of pain. Physiol Behav. 1974 May;12(5):805-11.

  6. Helmstetter FJ, Tershner SA. Lesions of the periaqueductal gray and rostral ventromedial medulla disrupt antinociceptive but not cardiovascular aversive conditional responses. J Neurosci. 1994. 14(11):7099-108.

  7. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965(150);971-9.

  8. Moayedi M, Davis KD. Theories of pain: from specifi city to gate control. J Neurophysiol. 2013 Jan;109(1):5- 12. doi: 10.1152/jn.00457.2012. Epub 2012 Oct 3.

  9. Collins JG, Kitahata LM, Matsumoto M, Homma E, Suzukawa M. Spinally administered epinephrine suppresses noxiously evoked activity of WDR neurons in the dorsal horn of the spinal cord. Anesthesiology. 1984 Apr;60(4):269-275.

  10. Maeda M, Tsuruoka M, Hayashi B, Nagasawa I, Inoue T. Descending pathways from activated locus coeruleus/ subcoeruleus following unilateral hindpaw infl ammation in the rat. Brain Res Bull. 2009 Mar 16;78(4- 5):170-4. doi: 10.1016/j.brainresbull.2008.09.005.

  11. Danzebrink RM, Gebhart GF. Antinociceptive effects of intrathecal adrenoceptor agonists in a rat model of visceral nociception. J Pharmacol Exp Ther. 1990 May;253(2):698-705.

  12. Fukuda T, Furukawa H, Hisano S, Toyooka H. Systemic clonidine activates neurons of the dorsal horn, but not the locus coeruleus (A6) or the A7 area, after a formalin test: the importance of the dorsal horn in the antinociceptive effects of clonidine. J Anesth. 2006;20(4):279-83.

  13. Takano Y, Yaksh TL. Characterization of the pharmacology of intrathecally administered alpha-2 agonists and antagonists in rats. J Pharmacol Exp Ther. 1992 May;261(2):764-72.

  14. Sierralta F, Naquira D, Pinardi G, Miranda HF. alpha- Adrenoceptor and opiod receptor modulation of clonidine-induced antinociception. Br J Pharmacol. Oct 1996; 119(3):551-4

  15. Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Sixth ed. Lippincott-Raven: Philadelphia; 1999.

  16. Atlas D, Melamed E. Direct mapping of beta-adrenergic receptors in the rat central nervous system by a novel fl uorescent beta-blocker. Brain Res. 1978 Jul 14;150(2):377-85.

  17. Choucair-Jaafar N, Yalcin I, Rodeau JL, Waltisperger E, Freund-Mercier MJ, Barrot M. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br J Pharmacol. 2009 Dec;158(7):1683-94. doi: 10.1111/j.1476-5381.2009.00510.x.

  18. Khanna NK, Dadhich AP, Vyas DS. Modifi cation of morphine analgesia by labetalol. Indian J Exp Biol. 1978 Oct;16(10):1091-2.

  19. Masaki E. Antinociceptive effects of landiolol and esmolol. Masui. 2006 Jul;55(7):849-55. Review. Japanese.

  20. Light KC, Bragdon EE, Grewen KM, Brownley KA, Girdler SS, Maixner W. Adrenergic dysregulation and pain with and without acute beta-blockade in women with fi bromyalgia and temporomandibular disorder. J Pain. 2009 May;10(5):542-52. doi: 10.1016/j. jpain.2008.12.006.

  21. Ashtari F, Shaygannejad V, Akbari M. A double- blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008 Nov;118(5):301-5. doi: 10.1111/j.1600-0404.2008.01087.x.

  22. Marsland AR, Weekes JW, Atkinson RL, Leong MG. Phantom limb pain: a case for beta blockers? Pain. 1982 Mar;12(3):295-7.

  23. Barrot M, Yalcin I, Choucair-Jaafar N, Benbouzid M, Freund-Mercier MJ. From antidepressant drugs to beta-mimetics: preclinical insights on potential new treatments for neuropathic pain. Recent Pat CNS Drug Discov. 2009 Nov;4(3):182-9.

  24. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. (Guest Editorial). Pain. 1983 Jun;16(2):109-10.

  25. Svendsen F, Hole K, Tjřlsen A. Long-term potentiation in single wide dynamic range neurons induced by noxious stimulation in intact and spinalized rats. Prog Brain Res. 2000;129:153-61.

  26. Bouhassira D, Bing Z, Le Bars D. Studies of brain structures involved in diffuse noxious inhibitory controls in the rat: the rostral ventromedial medulla. J Physiol. 1993 Apr;463:667-87.

  27. Dickenson A, Ashwood N, Sullivan AF, James I, Dray A. Antinociception produced by capsaicin: spinal or peripheral mechanism? Eur J Pharmacol. 1990 Oct 9;187(2):225-33.

  28. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. The epidural clonidine study group. Epidural clonidine analgesia for intractable cancer pain. Pain. 1995 Jun;61(3):391-9.

  29. Nicholas AP, Hokfelt T, Pieribone VA. The distribution and signifi cance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci 17:245-55.

  30. Pertovaara A, Almeida A. Endogenous pain modulation: descending inhibitory systems, in Handbook of Clinical Neurology, Pain. 3rd series, vol. 3, 2006, pp. 179-192.

  31. Kobilka BK. Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci. Apr 2011; 32(4): 213-8.

  32. Melzack R, Wall PD. On the nature of cutaneous sensory mechanisms. Brain. 1962;85(2):331-56 doi:10.1093/brain/85.2.331.




2020     |     www.medigraphic.com